Self-assembled peptide/polymer hybrid nanoplatform for cancer immunostimulating therapies.
Cancer vaccine
Hybrid nanoparticles
MAGE-A3
Nanovaccines
Self-assembling peptide
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
18 Sep 2023
18 Sep 2023
Historique:
accepted:
04
08
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
aheadofprint
Résumé
Integrating peptide epitopes in self-assembling materials is a successful strategy to obtain nanovaccines with high antigen density and improved efficacy. In this study, self-assembling peptides containing MAGE-A3/PADRE epitopes were designed to generate functional therapeutic nanovaccines. To achieve higher stability, peptide/polymer hybrid nanoparticles were formulated by controlled self-assembly of the engineered peptides. The nanoparticles showed good biocompatibility to both human red blood- and dendritic cells. Incubation of the nanoparticles with immature dendritic cells triggered immune effects that ultimately activated CD8 + cells. The antigen-specific and IgG antibody responses of healthy C57BL/6 mice vaccinated with the nanoparticles were analyzed. The in vivo results indicate a specific response to the nanovaccines, mainly mediated through a cellular pathway. This research indicates that the immunogenicity of peptide epitope vaccines can be effectively enhanced by developing self-assembled peptide-polymer hybrid nanostructures.
Identifiants
pubmed: 37721693
doi: 10.1007/s13346-023-01410-y
pii: 10.1007/s13346-023-01410-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerio de Ciencia e Innovación
ID : PID2021-124986OB-I00
Organisme : Instituto de Salud Carlos III
ID : AC21_2/00046
Organisme : Tehran University of Medical Sciences and Health Services
ID : 35632
Informations de copyright
© 2023. The Author(s).
Références
Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970.
Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology e-book. Elsevier Health Sciences; 2017.
Alexander J, del Guercio M-F, Maewal A, Qiao L, Fikes J, Chesnut RW, et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 2000;164(3):1625. https://doi.org/10.4049/jimmunol.164.3.1625 .
doi: 10.4049/jimmunol.164.3.1625
pubmed: 10640784
He X, Abrams SI, Lovell JF. Peptide delivery systems for cancer vaccines. Adv Ther. 2018;1(5):1800060. https://doi.org/10.1002/adtp.201800060 .
doi: 10.1002/adtp.201800060
Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859–74. https://doi.org/10.1038/sj.leu.2404787 .
doi: 10.1038/sj.leu.2404787
pubmed: 17611570
Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11(22):8055–62. https://doi.org/10.1158/1078-0432.CCR-05-1203 .
doi: 10.1158/1078-0432.CCR-05-1203
pubmed: 16299236
Kim Y-D, Park H-R, Song M-H, Shin D-H, Lee C-H, Lee M-K, et al. Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med. 2012;29(4):656–62. https://doi.org/10.3892/ijmm.2012.896 .
doi: 10.3892/ijmm.2012.896
pubmed: 22294213
pmcid: 3573764
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35. https://doi.org/10.1016/S1470-2045(16)00099-1 .
doi: 10.1016/S1470-2045(16)00099-1
pubmed: 27132212
Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242–9. https://doi.org/10.1002/eji.1830230929 .
doi: 10.1002/eji.1830230929
pubmed: 7690326
Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med. 1995;182(1):261–6. https://doi.org/10.1084/jem.182.1.261 .
doi: 10.1084/jem.182.1.261
pubmed: 7540654
Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93(15):7855–60. https://doi.org/10.1073/pnas.93.15.7855 .
doi: 10.1073/pnas.93.15.7855
pubmed: 8755566
pmcid: 38838
Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol. 2013;25(2):182–90. https://doi.org/10.1016/j.smim.2013.04.008 .
doi: 10.1016/j.smim.2013.04.008
pubmed: 23706598
Bijker MS, Melief CJM, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 2007;6(4):591–603. https://doi.org/10.1586/14760584.6.4.591 .
doi: 10.1586/14760584.6.4.591
pubmed: 17669012
Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm. 2008;5(3):464–71. https://doi.org/10.1021/mp700126c .
doi: 10.1021/mp700126c
pubmed: 18266319
pmcid: 2690700
De Geest BG, Willart MA, Hammad H, Lambrecht BN, Pollard C, Bogaert P, et al. Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. ACS Nano. 2012;6(3):2136–49. https://doi.org/10.1021/nn205099c .
doi: 10.1021/nn205099c
pubmed: 22303914
Dimier-Poisson I, Carpentier R, Nguyen TTL, Dahmani F, Ducournau C, Betbeder D. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. 2015;50:164–75. https://doi.org/10.1016/j.biomaterials.2015.01.056 .
doi: 10.1016/j.biomaterials.2015.01.056
pubmed: 25736506
Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109–46. https://doi.org/10.1021/acs.chemrev.5b00109 .
doi: 10.1021/acs.chemrev.5b00109
pubmed: 26154342
pmcid: 4688911
Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015;40:88–97. https://doi.org/10.1016/j.biomaterials.2014.10.053 .
doi: 10.1016/j.biomaterials.2014.10.053
pubmed: 25465442
Thomas C, Rawat A, Hope-Weeks L, Ahsan F. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to Hepatitis B vaccine. Mol Pharm. 2011;8(2):405–15. https://doi.org/10.1021/mp100255c .
doi: 10.1021/mp100255c
pubmed: 21189035
van Hell AJ, Costa CICA, Flesch FM, Sutter M, Jiskoot W, Crommelin DJA, et al. Self-assembly of recombinant amphiphilic oligopeptides into vesicles. Biomacromol. 2007;8(9):2753–61. https://doi.org/10.1021/bm0704267 .
doi: 10.1021/bm0704267
Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet. 2005;6(4):299–310. https://doi.org/10.1038/nrg1577 .
doi: 10.1038/nrg1577
pubmed: 15761468
Rudra JS, Tian YF, Jung JP, Collier JH. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A. 2010;107(2):622–7. https://doi.org/10.1073/pnas.0912124107 .
doi: 10.1073/pnas.0912124107
pubmed: 20080728
Rad-Malekshahi M, Fransen MF, Krawczyk M, Mansourian M, Bourajjaj M, Chen J, et al. Self-assembling peptide epitopes as novel platform for anticancer vaccination. Mol Pharm. 2017;14(5):1482–93. https://doi.org/10.1021/acs.molpharmaceut.6b01003 .
doi: 10.1021/acs.molpharmaceut.6b01003
pubmed: 28088862
pmcid: 5415879
Dimitrov I, Flower DR, Doytchinova I. AllerTOP - a server for in silico prediction of allergens. BMC Bioinformatics. 2013;14(6):S4. https://doi.org/10.1186/1471-2105-14-S6-S4 .
doi: 10.1186/1471-2105-14-S6-S4
pubmed: 23735058
pmcid: 3633022
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery Consortium, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE. 2013;8(9):e73957. https://doi.org/10.1371/journal.pone.0073957 .
doi: 10.1371/journal.pone.0073957
pubmed: 24058508
pmcid: 3772798
Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol (Clifton, NJ). 1999;112:531–52. https://doi.org/10.1385/1-59259-584-7:531 .
doi: 10.1385/1-59259-584-7:531
Merrifield B. Solid phase synthesis. Science. 1986;232(4748):341–7. https://doi.org/10.1126/science.3961484 .
doi: 10.1126/science.3961484
pubmed: 3961484
Merrifield RB. Solid phase synthesis (Nobel Lecture). Angew Chem Int Ed Engl. 1985;24(10):799–810. https://doi.org/10.1002/anie.198507993 .
doi: 10.1002/anie.198507993
Vemuri S. Comparison of assays for determination of peptide content for lyophilized thymalfasin. J Pept Res. 2005;65(4):433–9. https://doi.org/10.1111/j.1399-3011.2005.00225.x .
doi: 10.1111/j.1399-3011.2005.00225.x
pubmed: 15813890
Zhang A, Zhang Z, Shi F, Ding J, Xiao C, Zhuang X, et al. Disulfide crosslinked PEGylated starch micelles as efficient intracellular drug delivery platforms. Soft Matter. 2013;9(7):2224–33. https://doi.org/10.1039/C2SM27189C .
doi: 10.1039/C2SM27189C
Li H-C, Hsieh F-J, Chen C-P, Chang M-Y, Hsieh PCH, Chen C-C, et al. The hemocompatibility of oxidized diamond nanocrystals for biomedical applications. Sci Rep. 2013;3(1):3044. https://doi.org/10.1038/srep03044 .
doi: 10.1038/srep03044
pubmed: 24157697
pmcid: 6505714
Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 2008;8(8):2180–7. https://doi.org/10.1021/nl0805615 .
doi: 10.1021/nl0805615
pubmed: 18605701
pmcid: 2613576
Posch W, Lass-Flörl C, Wilflingseder D. Generation of human monocyte-derived dendritic cells from whole blood. J Vis Exp: JoVE. 2016. https://doi.org/10.3791/54968 .
doi: 10.3791/54968
pubmed: 28060313
pmcid: 5226452
Tedder TF, Jansen PJ. Isolation and generation of human dendritic cells. Curr Protoc Immunol. 1997;23(1):7–32. https://doi.org/10.1002/0471142735.im0732s23 .
doi: 10.1002/0471142735.im0732s23
Robla S, Prasanna M, Varela-Calviño R, Grandjean C, Csaba N. A chitosan-based nanosystem as pneumococcal vaccine delivery platform. Drug Deliv Transl Res. 2021;11(2):581–97. https://doi.org/10.1007/s13346-021-00928-3 .
doi: 10.1007/s13346-021-00928-3
pubmed: 33655441
Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1(9):751–61. https://doi.org/10.1016/S1074-7613(94)80017-0 .
doi: 10.1016/S1074-7613(94)80017-0
pubmed: 7895164
Bergmann CC, Yao Q, Ho CK, Buckwold SL. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol. 1996;157(8):3242–9. https://doi.org/10.4049/jimmunol.157.8.3242 .
doi: 10.4049/jimmunol.157.8.3242
pubmed: 8871618
Uebel S, Kraas W, Kienle S, Wiesmüller K-H, Jung G, Tampé R. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Proc Natl Acad Sci. 1997;94(17):8976–81. https://doi.org/10.1073/pnas.94.17.8976 .
doi: 10.1073/pnas.94.17.8976
pubmed: 9256420
pmcid: 22991
Ree R, Varland S, Arnesen T. Spotlight on protein N-terminal acetylation. Exp Mol Med. 2018;50(7):1–13. https://doi.org/10.1038/s12276-018-0116-z .
doi: 10.1038/s12276-018-0116-z
pubmed: 30054468
pmcid: 6063853
Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012;40(Web Server issue):W525–30. https://doi.org/10.1093/nar/gks438 .
doi: 10.1093/nar/gks438
pubmed: 22610854
pmcid: 3394288
Radmalekshahi M. Self-assembled peptide nanostructures: production, structural characterization and in vivo application as cancer vaccine. Utrecht University; 2015. https://dspace.library.uu.nl/handle/1874/325244 . Accessed 21 Sept 2021.
Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 2005;62(9):1025–37. https://doi.org/10.1007/s00018-005-4528-2 .
doi: 10.1007/s00018-005-4528-2
pubmed: 15868101
Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinf. 2007;8:238. https://doi.org/10.1186/1471-2105-8-238 .
doi: 10.1186/1471-2105-8-238
De Temmerman ML, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discovery Today. 2011;16(13–14):569–82. https://doi.org/10.1016/j.drudis.2011.04.006 .
doi: 10.1016/j.drudis.2011.04.006
pubmed: 21570475
Storni T, Kündig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3):333–55. https://doi.org/10.1016/j.addr.2004.09.008 .
doi: 10.1016/j.addr.2004.09.008
pubmed: 15560945
Csaba N, Caamaño P, Sanchez A, Dominguez F, Alonso MJ. PLGA: poloxamer and PLGA: poloxamine blend nanoparticles: new carriers for gene delivery. Biomacromol. 2005;6(1):271–8.
doi: 10.1021/bm049577p
Csaba N, Sanchez A, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release. 2006;113(2):164–72. https://doi.org/10.1016/j.jconrel.2006.03.017 .
doi: 10.1016/j.jconrel.2006.03.017
pubmed: 16759732
d’Angelo I, Garcia-Fuentes M, Parajó Y, Welle A, Vántus T, Horváth A, et al. Nanoparticles based on PLGA: poloxamer blends for the delivery of proangiogenic growth factors. Mol Pharm. 2010;7(5):1724–33. https://doi.org/10.1021/mp1001262 .
doi: 10.1021/mp1001262
pubmed: 20681555
Parajó Y, d’Angelo I, Horváth A, Vantus T, György K, Welle A, et al. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors. Eur J Pharm Sci. 2010;41(5):644–9. https://doi.org/10.1016/j.ejps.2010.09.008 .
doi: 10.1016/j.ejps.2010.09.008
pubmed: 20869438
Santander-Ortega MJ, Jódar-Reyes AB, Csaba N, Bastos-González D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci. 2006;302(2):522–9. https://doi.org/10.1016/j.jcis.2006.07.031 .
doi: 10.1016/j.jcis.2006.07.031
pubmed: 16887138
Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, et al. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019;14(3):287–97. https://doi.org/10.1038/s41565-018-0358-x .
doi: 10.1038/s41565-018-0358-x
pubmed: 30692673
Tobío M, Nolley J, Guo Y, McIver J, José AM. A Novel System Based on a Poloxamer/ PLGA Blend as a Tetanus Toxoid Delivery Vehicle. Pharm Res. 1999;16(5):682–8. https://doi.org/10.1023/A:1018820507379 .
doi: 10.1023/A:1018820507379
pubmed: 10350011
Sánchez A, Tobı́o M, González L, Fabra A, Alonso MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci. 2003;18(3–4):221–9. https://doi.org/10.1016/s0928-0987(03)00019-8 .
Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A Review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709–28. https://doi.org/10.1007/s11095-006-9104-4 .
doi: 10.1007/s11095-006-9104-4
pubmed: 17096184
Mandal BB, Kundu SC. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery. Nanotechnology. 2009;20(35):355101. https://doi.org/10.1088/0957-4484/20/35/355101 .
doi: 10.1088/0957-4484/20/35/355101
pubmed: 19671963
Abellan-Pose R, Teijeiro-Valiño C, Santander-Ortega MJ, Borrajo E, Vidal A, Garcia-Fuentes M, et al. Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size. Int J Pharm. 2016;509(1):107–17. https://doi.org/10.1016/j.ijpharm.2016.05.034 .
doi: 10.1016/j.ijpharm.2016.05.034
pubmed: 27210735
Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148–54.
doi: 10.4049/jimmunol.173.5.3148
pubmed: 15322175
Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315–22. https://doi.org/10.1016/j.ijpharm.2005.03.035 .
doi: 10.1016/j.ijpharm.2005.03.035
pubmed: 15961266
Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85–94. https://doi.org/10.1208/s12248-012-9418-6 .
doi: 10.1208/s12248-012-9418-6
pubmed: 23054976
Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095–107. https://doi.org/10.1586/erv.10.89 .
doi: 10.1586/erv.10.89
pubmed: 20822351
pmcid: 2963573
Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine. 2004;22(15):1903–13. https://doi.org/10.1016/j.vaccine.2003.11.008 .
doi: 10.1016/j.vaccine.2003.11.008
pubmed: 15121302
Bhattacharjee S. DLS and zeta potential - What they are and what they are not? J Control Release. 2016;235:337–51. https://doi.org/10.1016/j.jconrel.2016.06.017 .
doi: 10.1016/j.jconrel.2016.06.017
pubmed: 27297779
Vicente S, Goins BA, Sanchez A, Alonso MJ, Phillips WT. Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules. Vaccine. 2014;32(15):1685–92. https://doi.org/10.1016/j.vaccine.2014.01.059 .
doi: 10.1016/j.vaccine.2014.01.059
pubmed: 24508040
Gao J, Ochyl LJ, Yang E, Moon JJ. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens. Int J Nanomedicine. 2017;12:1251–64. https://doi.org/10.2147/ijn.s125866 .
doi: 10.2147/ijn.s125866
pubmed: 28243087
pmcid: 5317250
Caputo F, Clogston J, Calzolai L, Rösslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Release. 2019;299:31–43. https://doi.org/10.1016/j.jconrel.2019.02.030 .
doi: 10.1016/j.jconrel.2019.02.030
pubmed: 30797868
Kato H, Nakamura A, Takahashi K, Kinugasa S. Accurate size and size-distribution determination of polystyrene latex nanoparticles in aqueous medium using dynamic light scattering and asymmetrical flow field flow fractionation with multi-angle light scattering. Nanomaterials. 2012;2(1):15–30.
doi: 10.3390/nano2010015
pubmed: 28348293
pmcid: 5327882
de la Harpe KM, Kondiah PPD, Choonara YE, Marimuthu T, du Toit LC, Pillay V. The hemocompatibility of nanoparticles: a review of cell-nanoparticle interactions and hemostasis. Cells. 2019;8(10):1209. https://doi.org/10.3390/cells8101209 .
doi: 10.3390/cells8101209
pubmed: 31591302
pmcid: 6829615
Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–713. https://doi.org/10.1016/j.addr.2006.09.017 .
doi: 10.1016/j.addr.2006.09.017
pubmed: 17118485
Crowe JH, Hoekstra FA, Crowe LM. Anhydrobiosis. Annu Rev Physiol. 1992;54(1):579–99. https://doi.org/10.1146/annurev.ph.54.030192.003051 .
doi: 10.1146/annurev.ph.54.030192.003051
pubmed: 1562184
Crowe LM, Reid DS, Crowe JH. Is trehalose special for preserving dry biomaterials? Biophys J. 1996;71(4):2087–93. https://doi.org/10.1016/S0006-3495(96)79407-9 .
doi: 10.1016/S0006-3495(96)79407-9
pubmed: 8889183
pmcid: 1233675
Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3(12):984–93. https://doi.org/10.1038/nri1246 .
doi: 10.1038/nri1246
pubmed: 14647480
Worbs T, Hammerschmidt SI, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol. 2017;17(1):30–48. https://doi.org/10.1038/nri.2016.116 .
doi: 10.1038/nri.2016.116
pubmed: 27890914
Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180(1):83–93. https://doi.org/10.1084/jem.180.1.83 .
doi: 10.1084/jem.180.1.83
pubmed: 8006603
Wischke C, Borchert H-H, Zimmermann J, Siebenbrodt I, Lorenzen DR. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release. 2006;114(3):359–68. https://doi.org/10.1016/j.jconrel.2006.06.020 .
doi: 10.1016/j.jconrel.2006.06.020
pubmed: 16889866
Al-Ashmawy G. Dendritic cell subsets, maturation and function. 2018.
D’Souza WN, Lefrançois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol. 2003;171(11):5727. https://doi.org/10.4049/jimmunol.171.11.5727 .
doi: 10.4049/jimmunol.171.11.5727
pubmed: 14634080
Pompano RR, Chen J, Verbus EA, Han H, Fridman A, McNeely T, et al. Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs. Adv Healthc Mater. 2014;3(11):1898–908. https://doi.org/10.1002/adhm.201400137 .
doi: 10.1002/adhm.201400137
pubmed: 24923735
pmcid: 4227912
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity. 2018;49(6):1148-61.e7. https://doi.org/10.1016/j.immuni.2018.09.024 .
doi: 10.1016/j.immuni.2018.09.024
pubmed: 30552023
pmcid: 6301092
Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179(8):5033–40. https://doi.org/10.4049/jimmunol.179.8.5033 .
doi: 10.4049/jimmunol.179.8.5033
pubmed: 17911588
El Bissati K, Zhou Y, Dasgupta D, Cobb D, Dubey JP, Burkhard P, et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32(26):3243–8. https://doi.org/10.1016/j.vaccine.2014.03.092 .
doi: 10.1016/j.vaccine.2014.03.092
pubmed: 24736000
pmcid: 4084734
Melief CJM, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351–60. https://doi.org/10.1038/nrc2373 .
doi: 10.1038/nrc2373
pubmed: 18418403
Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol. 2009;183(11):7268. https://doi.org/10.4049/jimmunol.0901957 .
doi: 10.4049/jimmunol.0901957
pubmed: 19915055
Azuar A, Li Z, Shibu MA, Zhao L, Luo Y, Shalash AO, et al. Poly(Hydrophobic Amino Acid)-Based Self-Adjuvanting Nanoparticles For Group A Streptococcus Vaccine Delivery. J Med Chem. 2021;64(5):2648–58. https://doi.org/10.1021/acs.jmedchem.0c01660 .
doi: 10.1021/acs.jmedchem.0c01660
pubmed: 33529034